AIxCrypto Launches "Agentir" to Enhance AI Agent Evaluation and Expand Ecosystem
- AIxCrypto launches "Agentir," enhancing performance evaluation of AI agents within its blockchain ecosystem.
- The company has 4.8 million registered wallet addresses, evidencing strong community engagement and growth.
- AIxCrypto focuses on AI-driven innovation and community interaction to lead in the AI-blockchain space.
AIxCrypto’s "Agentir" Launches to Evaluate AI Agents and Expand Its Ecosystem
AIxCrypto Inc. (NASDAQ: AIXC), a pioneering company in the fusion of artificial intelligence (AI) and blockchain technology, launches a significant expansion with its latest initiative, "Agentir." This new environment is crafted specifically for the performance evaluation of AI agents, marking a strategic move to enhance the utility and functionality of AI within the blockchain sphere. The launch occurs against the backdrop of impressive growth metrics for AIxC, demonstrating the company’s ambitious efforts to become a leader at the convergence of Web2 and Web3.
Currently, AIxCrypto boasts a remarkable 4.8 million registered wallet addresses, with 3.7 million accruing utility points, showcasing an engaged user base. The firm has cultivated a vibrant community via multiple platforms, amassing 198,000 linked Twitter accounts, 139,000 on Discord, and 33,000 on Telegram. In just the last month, the AIxC Hub has seen an extraordinary growth rate of 336%, adding over 3.7 million new registered addresses, and increasing its network footprint by more than four times since its inception. This surge in participation is a clear indication of the growing interest in AI-driven solutions that AIxCrypto is fostering.
The launch of Hub S2 signifies a pivotal moment for AIxCrypto, promoting deeper integration of AI agent ownership and modular development. This feature allows users to interact with AI agents and take part in structured prediction competitions. By simplifying the creation of AI-driven products through modular building blocks and intuitive natural-language tools, AIxCrypto is well-positioned to roll out future innovations centered on AI Agents. These efforts aim not only to enhance benchmarking capabilities but also to establish collaborative frameworks within its evolving Hub ecosystem, solidifying the company's competitive edge in the dynamic AI-blockchain landscape.
In addition to the successful launch of Agentir, AIxCrypto's ongoing commitment to engaging its community is evident in the steady growth of its Discord community, which now boasts over 59,000 members. The company’s social media platforms, particularly its X account with over 52,000 followers, reflect its growing visibility and influence in the tech community. The impressive expansion of registered user accounts alongside enhanced community engagement strengthens AIxCrypto's position as it navigates the evolving demands of the AI and blockchain sectors.
As the intersection between AI and blockchain continues to evolve, AIxCrypto Holdings aligns itself with the trends driving user engagement and technological innovation. By leveraging modular AI products and fostering community interaction, AIxCrypto is set to play a significant role in shaping the future of decentralized technology, ensuring that it remains at the forefront of industry advancements.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…